Advos

SoundHound AI reported a 52% year-over-year revenue increase to $44.2 million in Q1 2026, driven by strong demand for its voice and agentic AI solutions, and reaffirmed its full-year revenue guidance of $225 million to $260 million.

Silver's steeper declines during market retreats are driven by lower liquidity and its dual role as both an industrial and monetary metal, but long-term prospects remain robust due to persistent supply deficits and growing industrial demand.

Ring Energy announced the pricing of a $60 million public offering to repay borrowings under its credit facility, aiming to strengthen its balance sheet.

Ideal Power announced a $30 million registered direct offering to fund commercialization of its B-TRAN bidirectional semiconductor power switch, targeting growing demand for power efficiency in data centers and industrial markets.

Cardio Diagnostics Holdings CEO Dr. Meesha Dogan discusses the company's precision medicine approach to cardiovascular disease, expansion into India through partnerships, and progress in Medicare reimbursement on the BioMedWire Podcast.

Datavault AI and Wellgistics Health form DelivMeds AI, a healthcare platform combining AI, blockchain, and biometrics, with expected asset value of $4 billion.

Nevada Organic Phosphate Inc. reported encouraging preliminary drill results from its Murdock Mountain property, intersecting 39 meters of target stratigraphy, indicating potential for a large-scale organic sedimentary phosphate deposit in North America.

SPARC AI Inc. has partnered with Rate Manufacturing to integrate its Overwatch platform into Rate's drones, enabling accurate navigation and targeting without GPS signals.

Yourgi has partnered with Pet Care Insurance to provide liability and pet injury coverage to all walkers, sitters, and boarders on its platform, enhancing protection for independent pet care providers.

Scientists at the University of North Carolina have engineered immune cells that selectively destroy acute myeloid leukemia while sparing healthy blood tissue, potentially expanding treatment options for patients.

The rapid maturation of quantum computing technology poses a significant threat to current encryption systems that protect digital data, raising urgent cybersecurity concerns.

Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced copper burden in Wilson’s disease models, expanding its therapeutic potential beyond its lead oncology program.

Safe Pro Group announced progress in integrating its SPOTD AI technology with Lantronix's System-on-Module platform for real-time robotic edge processing, expanding defense and commercial markets through edge-native AI that eliminates cloud dependence.

Rail Vision's majority-owned subsidiary Quantum Transportation has integrated a Google Quantum AI dataset into its quantum error correction pipeline, advancing scalable neural quantum error correction systems.

Lahontan Gold Corp. updates on Santa Fe Mine project progress, including geotechnical drilling, permitting, and exploration, with full funding secured through 2027.

Annovis Bio (NYSE: ANVS) has announced a proposed public offering of common stock and warrants to fund the Phase 3 clinical development of buntanetap for Alzheimer's disease.

GeoVax Labs comments on the WHO-declared PHEIC for Bundibugyo Ebola, emphasizing the limitations of strain-specific vaccines and the strategic importance of adaptable MVA-based platforms for multiple hemorrhagic fever threats.

SPARC AI Inc. has partnered with U.S. defense manufacturer Rate Manufacturing to integrate its Overwatch platform into multi-mission drones, enabling accurate navigation and targeting in GPS-denied environments.

Cardio Diagnostics Holdings CEO Dr. Meesha Dogan discusses the company's precision medicine approach to cardiovascular disease, its expansion into India through partnerships, and progress in the Medicare reimbursement process.

Scinai Immunotherapeutics Ltd. appointed Eilon Elmalem as site head of its Yavne CDMO facility to oversee operations and engineering as the company expands its contract development and manufacturing platform.

Annovis Bio has priced an underwritten public offering expected to raise $15 million, with proceeds aimed at advancing clinical development of its lead drug candidate, buntanetap, for Alzheimer's and Parkinson's diseases.